Sunstone participates in EUR 39m financing round of Targed Biopharma
An investor syndicate including venture capital firm Sunstone Life Science Ventures and Norwegian Hadean ventures has injected EUR 39m into Dutch biotech company Targed Biopharmaceuticals, which develops treatments for blood-clotting disorders.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Dutch biotech company Targed Biopharmaceuticals has evidently drawn attention to its treatment approach for blood-clotting disorders, also known as thrombotic diseases, as an investor syndicate has just injected EUR 39m into the company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Set-in-stone criteria will reduce risk for new biotech fund
For subscribers
.jpg&w=384&q=75)
